Compare Roundhill Magnificent Seven ETF (MAGS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs TG Therapeutics Inc — how do they compare? Roundhill Magnificent Seven ETF trades at $67.66, while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). Which is the better fit depends on your goals.
| MAGS | TGTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $59.06 |
52-Week Low | $55.39 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $67.71, down 1.93% amid broader rotation away from concentrated tech exposure. Technical indicators show bullish moving averages but overbought RSI levels, with key support at $67. Recent news highlights the ETF's 181% gain since launch but notes underperformance versus the S&P 500 this year as AI spending pressures tech balance sheets.
The ETF faces headwinds from compressed hyperscaler valuations and declining payout ratios, though AI revenue growth potential remains. Risks include concentration in seven mega-caps and market broadening away from tech leadership. Analyst sentiment is mixed, balancing long-term AI themes against near-term valuation concerns.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
